Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZW191 · 1 trial · 1 indication
Number of participants who experienced a DLT. DLTs include specifically defined adverse events (AEs) considered to be related to ZW191
Number of participants who experienced AEs, adverse events of special interest (AESIs), or serious adverse events (SAEs)
Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0
Number of participants who achieved a best overall response of either confirmed complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
| Arm | Type | Description |
|---|---|---|
| ZW191 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ZW191 | DRUG | Administered intravenously |
Inclusion Criteria: * Pathologically or cytologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable), recurrent and/or metastatic disease. * Measurable disease per RECIST v1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. * Adequat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ZW191 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is in Phase 1 clinical development and is not approved for any indication. The ongoing study enrolls adults with advanced solid tumors across the United States, Australia, Japan, Singapore, South Korea, and Spain.
ZW191 targets folate receptor alpha, also known as FR alpha, a protein expressed on certain tumor cells. By binding this target, ZW191 is designed to deliver its anti-tumor activity to FR alpha positive cancers. It is a small molecule therapeutic being developed for advanced solid tumors.
ZW191 is being developed by Zymeworks Inc., a biopharmaceutical company listed on the Nasdaq under the ticker ZYME. Zymeworks is the sponsor of the Phase 1 clinical trial evaluating ZW191 in patients with advanced solid tumors.
ZW191 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA or any regulatory authority. The Phase 1 trial is currently active and recruiting participants with advanced solid tumors.
ZW191 is being evaluated in a single Phase 1 trial, NCT06555744, titled A Study of ZW191 in Participants With Solid Tumors. The trial has an estimated enrollment of 145 adults and is currently active but not recruiting. It is an open-label, uncontrolled study.